Three-Dimensional Quantitative Tumor Response and Survival Analysis of Hepatocellular Carcinoma Patients Who Failed Initial Transarterial Chemoembolization: Repeat or Switch Treatment?

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Jul 27

PMID 35892874

Authors

Yan Zhao

Reham R Haroun

Sonia Sahu

Ruediger E Schernthaner

Susanne Smolka

Ming-De Lin

Kelvin K Hong

Christos Georgiades

Rafael Duran

Affiliations

Soon will be listed here.

Abstract

Objectives: The purpose of this study was to assess treatment responses and evaluate survival outcomes between responders and non-responders after each transarterial chemoembolization (TACE) session using the 3D quantitative criteria of the European Association for the Study of the Liver (qEASL) in hepatocellular carcinoma (HCC) patients.

Methods: A total of 94 consecutive patients who underwent MR imaging before and after TACE were retrospectively included. Volumetric tumor enhancement (qEASL) was expressed in cubic centimeters (cm). The Kaplan-Meier method with the log-rank test was used to calculate the overall survival (OS) for the non-/responders.

Results: In total, 28 (29.8%) patients showed a response after the first TACE. These responders demonstrated a clear trend toward longer OS compared with the non-responders (36.7 vs. 21.5 months, = 0.071). Of the 43 initial non-responders who underwent a second TACE within 3 months and had complete follow-up imaging, 15/43 (34.9%) achieved a response, and their median OS was significantly longer than that of the 28 non-responders to the second TACE (47.8 vs. 13.6 months, = 0.01). Furthermore, there was no significant difference in OS between the 28 patients who achieved a response after the first TACE and the 15 initial non-responders who achieved a response after the second TACE (36.7 vs. 47.8 months, = 0.701). The difference in OS between the responders and non-responders after the third TACE was not significant (11.4 months vs. 13.5 months, = 0.986).

Conclusion: Our study quantitatively demonstrated that a second TACE can be beneficial in terms of tumor response and survival for HCC patients who do not initially respond to TACE.

Citing Articles

Segmentation method of magnetic resonance imaging brain tumor images based on improved UNet network.

Yang Y, Wang P, Yang Z, Zeng Y, Chen F, Wang Z Transl Cancer Res. 2024; 13(3):1567-1583.

PMID: 38617525 PMC: 11009801. DOI: 10.21037/tcr-23-1858.

References

Chen S, Peng Z, Zhang Y, Chen M, Li J, Guo R . Lack of Response to Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Abandon or Repeat?. Radiology. 2021; 298(3):680-692. DOI: 10.1148/radiol.2021202289. View

Georgiades C, Geschwind J, Harrison N, Hines-Peralta A, Liapi E, Hong K . Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment?. Radiology. 2012; 265(1):115-23. PMC: 4137783. DOI: 10.1148/radiol.12112264. View

Lin M, Pellerin O, Bhagat N, Rao P, Loffroy R, Ardon R . Quantitative and volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors measurements: feasibility of a semiautomated software method to assess tumor response after transcatheter arterial.... J Vasc Interv Radiol. 2012; 23(12):1629-37. PMC: 3579576. DOI: 10.1016/j.jvir.2012.08.028. View

Granito A, Facciorusso A, Sacco R, Bartalena L, Mosconi C, Cea U . TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma. J Pers Med. 2021; 11(10). PMC: 8539564. DOI: 10.3390/jpm11101041. View

Gonzalez-Guindalini F, Botelho M, Harmath C, Sandrasegaran K, Miller F, Salem R . Assessment of liver tumor response to therapy: role of quantitative imaging. Radiographics. 2013; 33(6):1781-800. DOI: 10.1148/rg.336135511. View

Tacher V, Lin M, Duran R, Yarmohammadi H, Lee H, Chapiro J . Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach. Radiology. 2015; 278(1):275-84. PMC: 4695977. DOI: 10.1148/radiol.2015142951. View

Duran R, Chapiro J, Frangakis C, Lin M, Schlachter T, Schernthaner R . Uveal Melanoma Metastatic to the Liver: The Role of Quantitative Volumetric Contrast-Enhanced MR Imaging in the Assessment of Early Tumor Response after Transarterial Chemoembolization. Transl Oncol. 2014; 7(4):447-55. PMC: 4202794. DOI: 10.1016/j.tranon.2014.05.004. View

Chapiro J, Duran R, Lin M, Schernthaner R, Lesage D, Wang Z . Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver. Eur Radiol. 2015; 25(7):1993-2003. PMC: 4458393. DOI: 10.1007/s00330-015-3595-5. View

Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A . BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2021; 76(3):681-693. PMC: 8866082. DOI: 10.1016/j.jhep.2021.11.018. View

10.

Bonekamp D, Bonekamp S, Halappa V, Geschwind J, Eng J, Corona-Villalobos C . Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma. Eur J Radiol. 2014; 83(3):487-96. PMC: 4380187. DOI: 10.1016/j.ejrad.2013.11.016. View

11.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

12.

Palmer D, Malagari K, Kulik L . Role of locoregional therapies in the wake of systemic therapy. J Hepatol. 2020; 72(2):277-287. DOI: 10.1016/j.jhep.2019.09.023. View

13.

Terzi E, Golfieri R, Piscaglia F, Galassi M, Dazzi A, Leoni S . Response rate and clinical outcome of HCC after first and repeated cTACE performed "on demand". J Hepatol. 2012; 57(6):1258-67. DOI: 10.1016/j.jhep.2012.07.025. View

14.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

15.

Cheng A, Amarapurkar D, Chao Y, Chen P, Geschwind J, Goh K . Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: Consensus recommendations and review by an International Expert Panel. Liver Int. 2013; 34(2):174-83. DOI: 10.1111/liv.12314. View

16.

Chapiro J, Wood L, Lin M, Duran R, Cornish T, Lesage D . Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis. Radiology. 2014; 273(3):746-58. PMC: 4263418. DOI: 10.1148/radiol.14140033. View

17.

Finn R, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020; 382(20):1894-1905. DOI: 10.1056/NEJMoa1915745. View

18.

Tacher V, Lin M, Chao M, Gjesteby L, Bhagat N, Mahammedi A . Semiautomatic volumetric tumor segmentation for hepatocellular carcinoma: comparison between C-arm cone beam computed tomography and MRI. Acad Radiol. 2013; 20(4):446-52. PMC: 3602801. DOI: 10.1016/j.acra.2012.11.009. View

19.

. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69(1):182-236. DOI: 10.1016/j.jhep.2018.03.019. View

20.

Corona-Villalobos C, Halappa V, Geschwind J, Bonekamp S, Reyes D, Cosgrove D . Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib. Eur Radiol. 2014; 25(2):380-90. PMC: 4324620. DOI: 10.1007/s00330-014-3412-6. View